Rib-X Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering – Genetic Engineering News

The Company’s pipeline also includes its preclinical RX-04 program, partnered with Sanofi, S.A., and other discovery stage anti-infective programs.